ArticleThoracic cancer2020

New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations.

Weisan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.